Transplantation Proceedings
Volume 36, Issue 2, Supplement , Pages S372-S377 , March 2004

Experience with cyclosporine in endogenous uveitis posterior

  • D.A Hesselink

      Affiliations

    • Internal Medicine, Renal Transplant Unit (D.A.H.), Erasmus Medical Center, Rotterdam, The Netherlands
    • Corresponding Author InformationAddress reprint requests to D.A. Hesselink, Room Ee 563a, Department of Internal Medicine, Renal Transplant Unit, Erasmus Medical Center, Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands.
    • ,
  • G.S Baarsma

      Affiliations

    • Department of Ophthalmology (G.S.B.), Eye Hospital Rotterdam, Rotterdam, The Netherlands
    • ,
  • R.W.A.M Kuijpers

      Affiliations

    • Ophthalmology (R.W.A.M.K.), Erasmus Medical Center, Rotterdam, The Netherlands
    • ,
  • P.M van Hagen

      Affiliations

    • Clinical Immunology (P.M.V.H.), Erasmus Medical Center, Rotterdam, The Netherlands

References 

  1. Borel JF, Feurer C, Gubler HU, et al.  Biological effects of cyclosporin A (a new antilymphocytic agent). Agents Actions. 1976;6:468
  2. Dick AD, Azim M, Forrester JV. Immunosuppressive therapy for chronic uveitis (optimising therapy with steroids and cyclosporin A). Br J Ophthalmol. 1997;81:1107
  3. McCluskey PJ, Towler HM, Lightman S. Management of chronic uveitis. BMJ. 2000;320:555
  4. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, et al.  Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332
  5. Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness (a literature survey). Br J Ophthalmol. 1996;80:844
  6. Caspi RR. Immune mechanisms in uveitis. Springer Semin Immunopathol. 1999;21:113
  7. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47:119
  8. Nussenblatt RB, Rodrigues MM, Wacker WB, et al.  Cyclosporin A. Inhibition of experimental autoimmune uveitis in Lewis rats. J Clin Invest. 1981;67:1228
  9. Nussenblatt RB, Rodrigues MM, Salinas-Carmona MC, et al.  Modulation of experimental autoimmune uveitis with cyclosporin A. Arch Ophthalmol. 1982;100:1146
  10. Nussenblatt RB, Palestine AG, Rook AH, et al.  Treatment of intraocular inflammatory disease with cyclosporin A. Lancet. 1983;2:235
  11. Nussenblatt RB, Palestine AG, Chan CC. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol. 1983;96:275
  12. Binder AI, Graham EM, Sanders MD, et al.  Cyclosporin A in the treatment of severe Behcet's uveitis. Br J Rheumatol. 1987;26:285
  13. Le Hoang P, Girard B, Deray G, et al.  Cyclosporine in the treatment of birdshot retinochoroidopathy. Transplant Proc. 1988;20:128
  14. BenEzra D, Cohen E, Chajek T, et al.  Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplant Proc. 1988;20:136
  15. Masuda K, Nakajima A, Urayama A, et al.  Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet. 1989;1:1093
  16. de Vries J, Baarsma GS, Zaal MJ, et al.  Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol. 1990;74:344
  17. Nussenblatt RB, Palestine AG, Chan CC, et al.  Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol. 1991;112:138
  18. Myers BD, Ross J, Newton L, et al.  Cyclosporine-associated chronic nephropathy. N Engl J Med. 1984;311:699
  19. McNally PG, Feehally J. Pathophysiology of cyclosporin A nephrotoxicity (experimental and clinical observations). Nephrol Dial Transplant. 1992;7:791
  20. Morales JM, Andres A, Rengel M, et al.  Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant. 2001;16(Suppl 1):121
  21. Palestine AG, Austin HA, Balow JE, et al.  Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med. 1986;314:1293
  22. Towler HM, Cliffe AM, Whiting PH, et al.  Low dose cyclosporin A therapy in chronic posterior uveitis. Eye. 1989;3:282
  23. Towler HM, Whiting PH, Forrester JV. Combination low dose cyclosporin A and steroid therapy in chronic intraocular inflammation. Eye. 1990;4:514
  24. Hooper PL, Kaplan HJ. Triple agent immunosuppression in serpiginous choroiditis. Ophthalmology. 1991;98:944; (discussion 951–2)
  25. Whitcup SM, Salvo EC, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet's disease. Am J Ophthalmol. 1994;118:39
  26. Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy. Ophthalmology. 1994;101:822
  27. Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis. Ophthalmology. 1996;103:365; (discussion 373–4)
  28. Özdal PC, Ortac S, Taskintuna I, et al.  Long-term therapy with low dose cyclosporin A in ocular Behcet's disease. Doc Ophthalmol. 2002;105:301
  29. Walton RC, Nussenblatt RB, Whitcup SM. Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents. Ophthalmology. 1998;105:2028
  30. Kilmartin DJ, Forrester JV, Dick AD. Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol. 1998;82:737
  31. Isnard Bagnis C, Tezenas Du Montcel S, Beaufils H, et al.  Long-term renal effects of low-dose cyclosporine in uveitis-treated patients (follow-up study). J Am Soc Nephrol. 2002;13:2962
  32. Klupp J, Holt DW, van Gelder T. How pharmacokinetic and pharmacodynamic drug monitoring can improve outcome in solid organ transplant recipients. Transpl Immunol. 2002;9:211
  33. Kahan BD. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation. 1985;40:457
  34. Rocha G, Deschenes J, Cantarovich M. Cyclosporine monitoring with levels 6 hours after the morning dose in patients with noninfectious uveitis. Ophthalmology. 1997;104:245
  35. Martin DF, DeBarge LR, Nussenblatt RB, et al.  Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J Immunol. 1995;154:922
  36. Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology. 1999;106:723
  37. Nussenblatt RB, Fortin E, Schiffman R, et al.  Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb (a phase I/II clinical trial). Proc Natl Acad Sci U S A. 1999;96:7462
  38. Reiff A, Takei S, Sadeghi S, et al.  Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. 2001;44:1411
  39. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al.  Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet. 2001;358:295
  40. Joseph A, Raj D, Dua HS, et al.  Infliximab in the treatment of refractory posterior uveitis. Ophthalmology. 2003;110:1449

PII: S0041-1345(04)00004-1

doi: 10.1016/j.transproceed.2004.01.003

Transplantation Proceedings
Volume 36, Issue 2, Supplement , Pages S372-S377 , March 2004

Article Tools